ZyVersa Therapeutics Inc. (ZVSA)
0.70
0.03 (5.26%)
At close: Apr 23, 2025, 3:59 PM
0.76
7.33%
Pre-market: Apr 24, 2025, 08:10 AM EDT
5.26% (1D)
| Bid | 0.72 |
| Market Cap | 1.81M |
| Revenue (ttm) | 26.08K |
| Net Income (ttm) | -2.41B |
| EPS (ttm) | -8.48 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -0.01 |
| Analyst | Strong Buy |
| Ask | 0.79 |
| Volume | 103,669 |
| Avg. Volume (20D) | 2,314,145 |
| Open | 0.69 |
| Previous Close | 0.67 |
| Day's Range | 0.67 - 0.74 |
| 52-Week Range | 0.55 - 6.70 |
| Beta | 0.68 |
About ZVSA
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, In...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 11, 2022
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ZVSA
Website https://www.zyversa.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ZVSA stock is "Strong Buy." The 12-month stock price forecast is $240, which is an increase of 33942.55% from the latest price.
Stock Forecasts5 months ago
+39.56%
ZyVersa Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
